Pharma Transaction and IPO Financial-Evidence Consultant

The mandate

The assignment addresses a defined financial-evidence gap: historical pharmaceutical accounts, transaction adjustments and IPO-readiness issues are not organised into a traceable basis that reviewers can test. The consultant will deliver a Transaction Financial-Evidence Readiness Pack, covering agreed entities and periods. It is neither a valuation opinion nor a promise that the business is ready to offer securities.

The six-month project starts on 19 October 2026 at four days weekly in Hyderabad, combining workshops with protected remote review. The deliverable includes historical financial bridges, material accounting judgement files, a diligence question log and a readiness issue register. The selected transaction or listing perimeter is agreed before extraction; broad corporate restructuring and financial-statement preparation remain outside the initial scope.

Milestone one on 18 December 2026 contains a signed evidence inventory, period and entity baseline, and a classification of missing support. Milestone two, due 18 February 2027, delivers tested historical bridges and draft judgement files challenged by retained controllers. Milestone three on 18 April 2027 is the corrected readiness pack, resolved or accepted exceptions and an independent retained-reviewer traceability exercise.

The transaction sponsor and global controller accept the outputs. Historical bridges must reconcile to approved accounts, adjustments must have documented rationale and evidence, and unresolved items must show ownership and decision deadlines. Reviewers must reproduce a selected bridge and trace a judgement to source records without consultant interpretation. External auditors, legal advisers and capital-market providers retain their own assessment and cannot be implied to endorse the pack.

The sponsor supplies approved accounts, transaction records, accounting policies and named reviewers with time to resolve issues. The consultant does not sign audit opinions, issue securities disclosures, conduct commercial diligence or calculate independent asset valuations. New entities, periods or valuation work require separate change approval. Project closure occurs when the evidence and replay tests pass, not when an acquisition or IPO eventually completes.

What you will own

• Define the agreed entity and period perimeter, linking historical accounts and transaction records to reviewer questions before expanding data requests across the entire business.
• Construct historical financial bridges with visible adjustment rationale, distinguishing recurring performance, framework differences and transaction-specific items rather than endorsing a single normalised earnings figure.
• Develop material accounting judgement files for selected pharma balances, recording source evidence, specialist dependencies and the approval needed for the proposed treatment.
• Organise diligence questions and missing support into a readiness register with accountable owners, evidence deadlines and escalation when a material conclusion remains unsupported.
• Test the draft pack with retained controllers, correcting inconsistent assumptions and ensuring that source records support the period comparisons presented to transaction reviewers.
• Transfer the final evidence pack through a witnessed traceability and reproduction exercise, preserving approved exceptions and the limits of the consultant's assurance scope.

Candidate qualifications

• Demonstrate substantive pharmaceutical controllership or transaction-finance delivery with a verifiable career chronology and senior responsibility. Present a diligence or IPO evidence pack you personally authored, the material issue it exposed and how acceptance was secured. A transaction title is insufficient without detailed financial artifacts and evidence of reviewer use.
• Show strong Ind AS, IFRS or US GAAP capability appropriate to prior work, including historical comparability, acquisition adjustments and judgement-heavy pharma balances. Explain a bridge where an apparently non-recurring item required deeper analysis before it could support the proposed narrative, and describe the reviewed conclusion.
• Bring practical diligence and readiness organisation, including data perimeter control, reviewer challenge and specialist dependencies. Evidence should show how you avoided presenting incomplete support as resolved and how accounting, valuation and legal responsibilities remained distinct. Candidates need not provide every independent opinion, but must know which conclusions cannot be supplied by the consulting pack.
• Prove fixed-fee project discipline and retained-user transfer under transaction pressure. Describe management of late records, expanded entity requests and unresolved judgements without weakening acceptance criteria. Confidential information must be handled securely, and final readiness must remain an evidence status rather than a guarantee of transaction completion or regulatory approval.

Application

Applications for this mandate are received in one way only: through the India Board Terminal's application process. It is automated end to end. Your Executive Passport travels to the mandate holder in its confidential form, your answers to the three questions below are read before anything else in your file, and every stage that follows is recorded on your applications page.

There is no address to write to and no intermediary to call. The mandate holder reads what the Terminal delivers and nothing else, which is what keeps the process the same for every applicant and keeps your name out of it until you release it. Applications close on 12 October 2026. Mandate reference PCT-CON-2026-IND-50.